SIMCERE PHARMAC. GRP LTD (S2P) — Capital Reinvestment Ratio
SIMCERE PHARMAC. GRP LTD (S2P) has a Capital Reinvestment Ratio of 0.43x as of December 2025, meaning it reinvests 0% of its operating cash flow (€2.01 Billion) in capital expenditures (€862.20 Million). Check S2P goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
SIMCERE PHARMAC. GRP LTD Capital Reinvestment Ratio (2022–2025)
This chart tracks SIMCERE PHARMAC. GRP LTD's Capital Reinvestment Ratio across 4 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of SIMCERE PHARMAC. GRP LTD.
Annual Capital Reinvestment Ratio for SIMCERE PHARMAC. GRP LTD (2022–2025)
Year-by-year Capital Reinvestment Ratio for SIMCERE PHARMAC. GRP LTD from 2022 to 2025. See free cash flow generation of SIMCERE PHARMAC. GRP LTD to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.43x | €2.01 Billion | €862.20 Million | ▼ -21.9% |
| 2024 | 0.55x | €1.39 Billion | €762.57 Million | ▼ -91.5% |
| 2023 | 6.49x | €151.05 Million | €979.86 Million | ▲ +1195.6% |
| 2022 | 0.50x | €1.35 Billion | €678.00 Million | — |